Please provide your email address to receive an email when new articles are posted on . FORT LAUDERDALE, Fla. — Rare cases of occlusive retinal vasculitis have occurred with intravitreal therapies, ...

A retrospective case series suggested that faricimab (Vabysmo) intravitreal injections may be associated with rare cases of noninfectious intraocular inflammation. Over a 22-month period, 12 eyes from ...

More recently established treatments for RVO have taken a giant leap forward from laser photocoagulation since intravitreally ...

Please provide your email address to receive an email when new articles are posted on . A literature search identified 70 eyes with retinal vasculitis or vascular occlusion following brolucizumab for ...

Each terminal choroidal arteriole supplies an independent lobule (segment) of the lamina choriocapillaris. Occlusion of these terminal arterioles produces a corresponding perfusion defect, and its ...

The American Society of Retina Specialists (ASRS) has received reports of at least six cases of occlusive retinal vasculitis following injection of pegcetacoplan (Syfovre) into the eye. In an email to ...

Apellis Pharmaceuticals (NASDAQ:APLS) said early Thursday that a total of ten cases of retinal vasculitis have been confirmed with two more suspected among recipients of its eye medication Syfovre.

Ocular manifestations are common among patients with all types of antineutrophil cytoplasmic antibody-associated vasculitis, and machine learning-based predictive models offer potential for early ...

What is behind the bilateral eye pain and failing vision affecting a 96-year-old woman with neovascular age-related macular degeneration (nAMD)? That's what ophthalmologists needed to determine when ...

Apellis Pharmaceuticals, Inc. shares dropped 37% following reports of eye inflammation cases related to its geographic atrophy treatment, Syfovre. The company reported six incidents of retinal ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Vabysmo ...

– RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration and diabetic macular edema – – Approval is based on two Phase III studies demonstrating ...